We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Actinium Pharmaceuticals (ATNM - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Actinium Pharmaceuticals is a member of the Medical sector. This group includes 901 individual stocks and currently holds a Zacks Sector Rank of #10. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. ATNM is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ATNM's full-year earnings has moved 57.10% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the most recent data, ATNM has returned 33.84% so far this year. At the same time, Medical stocks have gained an average of 1.67%. This means that Actinium Pharmaceuticals is performing better than its sector in terms of year-to-date returns.
Looking more specifically, ATNM belongs to the Medical - Drugs industry, a group that includes 170 individual stocks and currently sits at #171 in the Zacks Industry Rank. This group has lost an average of 6.69% so far this year, so ATNM is performing better in this area.
ATNM will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Actinium Pharmaceuticals (ATNM - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Actinium Pharmaceuticals is a member of the Medical sector. This group includes 901 individual stocks and currently holds a Zacks Sector Rank of #10. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. ATNM is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ATNM's full-year earnings has moved 57.10% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the most recent data, ATNM has returned 33.84% so far this year. At the same time, Medical stocks have gained an average of 1.67%. This means that Actinium Pharmaceuticals is performing better than its sector in terms of year-to-date returns.
Looking more specifically, ATNM belongs to the Medical - Drugs industry, a group that includes 170 individual stocks and currently sits at #171 in the Zacks Industry Rank. This group has lost an average of 6.69% so far this year, so ATNM is performing better in this area.
ATNM will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.